Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: Low seroprevalence and non-cross-reactivity with Ad5

Journal of Virology

Volumn 78, Issue 23, 2004, Pages 13207-13215

  Holterman, Lennart ^a   Vogels, Ronald ^a   Van Der Vlugt, Remko ^a   Sieuwerts, Martijn ^a   Grimbergen, Jos ^b   Kaspers, Jorn ^a   Geelen, Eric ^a   Van Der Helm, Esmeralda ^a   Lemckert, Angelique ^a   Gillissen, Gert ^a   Verhaagh, Sandra ^a   Custers, Jerome ^a   Zuijdgeest, David ^a   Berkhout, Ben ^d   Bakker, Margreet ^d   Quax, Paul ^b,c   Goudsmit, Jaap ^a   Havenga, Menzo ^a,e  

^a CRUCELL HOLLAND BV   (Netherlands)

^b TNO   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e NONE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GREEN FLUORESCENT PROTEIN; NEUTRALIZING ANTIBODY;

ADENOVIRUS; ADENOVIRUS 11; ADENOVIRUS 5; ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CROSS REACTION; DENDRITIC CELL; GENE THERAPY; GENE TRANSFER; GENOME ANALYSIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; NONHUMAN; PLANT GROWTH; PLASMID; PRIORITY JOURNAL; SEROPREVALENCE; SMOOTH MUSCLE FIBER; SYNOVIOCYTE; VACCINATION; VASCULAR TISSUE; VIRUS REPLICATION;

ADENOVIRUSES, HUMAN; ADULT; AGED; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, CD; ANTIGENS, CD46; CROSS REACTIONS; GENE THERAPY; GENETIC VECTORS; HUMANS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MIDDLE AGED; SEROEPIDEMIOLOGIC STUDIES; TROPISM; VACCINATION; VIRUS REPLICATION;

EID: 8644281993     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.23.13207-13215.2004     Document Type: Article

References (43)

1. Barouch, D. H., P. F. McKay, S. M. Sumida, S. Santra, S. S. Jackson, D. A. Gorgone, M. A. Lifton, B. K. Chakrabarti, L. Xu, G. J. Nabel, and N. L. Letvin. 2003. Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines. J. Virol. 77:8729-8735.
2. Beer, S. J., C. B. Matthews, C. S. Stein, B. D. Ross, J. M. Hilfinger, and B. L. Davidson. 1998. Poly (lactic-glycolic) acid copolymer encapsulation of recombinant adenovirus reduces immunogenicity in vivo. Gene Ther. 5:740-746.
3. Casimiro, D. R., L. Chen, T.-M. Fu, R. K. Evans, M. J. Caulfield, M.-E. Davies, A. Tang, M. Chen, L. Huang, V. Harris, D. C. Freed, K. A. Wilson, S. Dubey, D.-M. Zhu, D. Nawrocki, H. Mach, R. Troutman, L. Isopi, D. Williams, W. Hurni, Z. Xu, J. G. Smith, S. Wang, X. Liu, L. Guan, R. Long, W. Trigona, G. J. Heidecker, H. C. Perry, N. Persaud, T. J. Toner, Q. Su, X. Liang, R. Youil, M. Chastain, A. J. Bett, D. B. Volkin, E. A. Emini, and J. W. Shiver. 2003. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J. Virol. 77:6305-6313.
4. Chillon, M., J. H. Lee, A. Fasbender, and M. J. Welsh. 1998. Adenovirus complexed with polyethylene glycol and cationic lipid is shielded from neutralizing antibodies in vitro. Gene Ther. 5:995-1002.
5. Clark, K. R., and P. R. Johnson. 2001. Gene delivery of vaccines for infectious disease. Curr. Opin. Mol. Ther. 3:375-384.
6. Crystal, R. G., N. G. McElvaney, M. A. Rosenfeld, C. S. Chu, A. Mastrangeli, J. G. Hay, S. L. Brody, H. A. Jane, N. T. Eissa, and C. Danel. 1994. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat. Genet. 8:42-51.
7. Emini, E. A. 2003. Status of the Mench HIV-1 vaccine program. Keystone Symposia on HIV-1 Vaccine Development, Banff, Canada.
8. Fallaux, F. J., A. Bout, I. van der Velde, D. J. van den Wollenberg, K. M. Hehir, J. Keegan, C. Auger, S. J. Cramer, H. van Ormondt, A. J. van der Eb, D. Valerio, and R. C. Hoeben. 1998. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum. Gene Ther. 9:1909-1917.
9. Gaggar, A., D. M. Shayakhmetov, and A. Lieber. 2003. CD46 is a cellular receptor for group B adenoviruses. Nat. Med. 9:1408-1412.
10. Gahery-Segard, H., V. Molinier-Frenkel, C. Le Boulaire, P. Saulnier, P. Opolon, R. Lengagne, E. Gautier, A. Le Cesne, L. Zitvogel, A. Venet, C. Schatz, M. Courtney, T. Le Chevalier, T. Tursz, J. G. Guillet, and F. Farace. 1997. Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products. J. Clin. Investig. 100:2218-2226.
11. Gruchal, M., H. Roy, S. Bhardwaj, and S. Yla-Herttuala. 2004. Gene therapy for cardiovascular diseases. Curr. Pharm. Des. 10:407-423.
12. Havenga, M. J., A. A. Lemckert, J. M. Grimbergen, R. Vogels, L. G. Huisman, D. Valerio, A. Bout, and P. H. Quax. 2001. Improved adenovirus vectors for infection of cardiovascular tissues. J. Virol. 75:3335-3342.
13. Hierholzer, J. C. 1992. Adenoviruses in the immunocompromised host. Clin. Microbiol. Rev. 5:262-274.
14. Hofmann, C., P. Loser, G. Cichon, W. Arnold, G. W. Both, and M. Strauss. 1999. Ovine adenovirus vectors overcome preexisting humoral immunity against human adenoviruses in vivo. J. Virol. 73:6930-6936.
15. Knowles, M. R., K. W. Hohneker, Z. Zhou, J. C. Olsen, T. L. Noah, P. C. Hu, M. W. Leigh, J. F. Engelhardt, L. J. Edwards, K. R. Jones, et al. 1995. A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N. Engl. J. Med. 333:823-831.
16. Kremer, E. J., S. Boutin, M. Chillon, and O. Danos. 2000. Canine adenovirus vectors: an alternative for adenovirus-mediated gene transfer. J. Virol. 74:505-512.
17. Liszewski, M. K., T. W. Post, and J. P. Atkinson. 1991. Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster. Annu. Rev. Immunol. 9:431-455.
18. Mei, Y. F., J. Skog, K. Lindman, and G. Wadell. 2003. Comparative analysis of the genome organization of human adenovirus 11, a member of the human adenovirus species B, and the commonly used human adenovirus 5 vector, a member of species C. J. Gen. Virol. 84:2061-2071.
19. Molnar-Kimber, K. L., D. H. Sterman, M. Chang, E. H. Kang, M. ElBash, M. Lanuti, A. Elshami, K. Gelfand, J. M. Wilson, L. R. Kaiser, and S. M. Albelda. 1998. Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Hum. Gene Ther. 9:2121-2133.
20. Post, T. W., M. K. Liszewski, E. M. Adams, I. Tedja, E. A. Miller, and J. P. Atkinson. 1991. Membrane cofactor protein of the complement system: alternative splicing of serine/threonine/proline-rich exons and cytoplasmic tails produces multiple isoforms that correlate with protein phenotype. J. Exp. Med. 174:93-102.
21. Puumalainen, A. M., M. Vapalahti, R. S. Agrawal, M. Kossila, J. Laukkanen, P. Lehtolainen, H. Viita, L. Paljarvi, R. Vanninen, and S. Yla-Herttuala. 1998. Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses. Hum. Gene Ther. 9:1769-1774.
22. Quax, P. H., J. M. Grimbergen, M. Lansink, A. H. Bakker, M. C. Blatter, D. Belin, V. W. van Hinsbergh, and J. H. Verheijen. 1998. Binding of human urokinase-type plasminogen activator to its receptor: residues involved in species specificity and binding. Arterioscler. Thromb. Vasc. Biol. 18:693-701.
23. Quax, P. H., M. L. Lamfers, J. H. Lardenoye, J. M. Grimbergen, M. R. de Vries, J. Slomp, M. C. de Ruiter, M. M. Kockx, J. H. Verheijen, and V. W. van Hinsbergh. 2001. Adenoviral expression of a urokinase receptor-targeted protease inhibitor inhibits neointima formation in murine and human blood vessels. Circulation 103:562-569.
24. Segerman, A., J. P. Atkinson, M. Marttila, V. Dennerquist, G. Wadell, and N. Arnberg. 2003. Adenovirus type 11 uses CD46 as a cellular receptor. J. Virol. 77:9183-9191.
25. Seshidhar Reddy, P., S. Ganesh, M. P. Limbach, T. Brann, A. Pinkstaff, M. Kaloss, M. Kaleko, and S. Connelly. 2003. Development of adenovirus serotype 35 as a gene transfer vector. Virology 311:384-393.
26. Seya, T., A. Hirano, M. Matsumoto, M. Nomura, and S. Ueda. 1999. Human membrane cofactor protein (MCP, CD46): multiple isoforms and functions. Int. J. Biochem. Cell Biol. 31:1255-1260.
27. Shabram, P. W., D. D. Giroux, A. M. Goudreau, R. J. Gregory, M. T. Horn, B. G. Huyghe, X. Liu, M. H. Nunnally, B. J. Sugarman, and S. Sutjipto. 1997. Analytical anion-exchange HPLC of recombinant type-5 adenoviral particles. Hum. Gene Ther. 8:453-465.
28. Shiver, J. W., T. M. Fu, L. Chen, D. R. Casimiro, M. E. Davies, R. K. Evans, Z. Q. Zhang, A. J. Simon, W. L. Trigona, S. A. Dubey, L. Huang, V. A. Harris, R. S. Long, X. Liang, L. Handt, W. A. Schleif, L. Zhu, D. C. Freed, N. V. Persaud, L. Guan, K. S. Punt, A. Tang, M. Chen, K. A. Wilson, K. B. Collins. G. J. Heidecker, V. R. Fernandez, H. C. Perry, J. G. Joyce, K. M. Grimm, J. C. Cook, P. M. Keller, D. S. Kresock, H. Mach, R. D. Troutman, L. A. Isopi, D. M. Williams, Z. Xu, K. E. Bohannon, D. B. Volkin, D. C. Montefiori, A. Miura, G. R. Krivulka, M. A. Lifton, M. J. Kuroda, J. E. Schmitz, N. L. Letvin, M. J. Caulfield, A. J. Bett, R. Youil, D. C. Kaslow, and E. A. Emini. 2002. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415:331-335.
29. Sirena, D., B. Lilienfeld, M. Eisenhut, S. Kalin, K. Boucke, R. R. Beerli, L. Vogt, C. Ruedl, M. F. Bachmann, U. F. Greber, and S. Hemmi. 2004. The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3. J. Virol. 78:4454-4462.
30. Sokoloff, A. V., I. Bock, G. Zhang, M. G. Sebestyen, and J. A. Wolff. 2000. The interactions of peptides with the innate immune system studied with use of T7 phage peptide display. Mol. Ther. 2:131-139.
31. Sprangers, M. C., W. Lakhai, W. Koudstaal, M. Verhoeven, B. F. Koel, R. Vogels, J. Goudsmit, M. J. Havenga, and S. Kostense. 2003. Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J. Clin. Microbiol. 41:5046-5052.
32. Stephenson, J. R. 2001. Genetically modified viruses: vaccines by design. Curr. Pharm. Biotechnol. 2:47-76.
33. Stone, D., A. Furthmann, V. Sandig, and A. Lieber. 2003. The complete nucleotide sequence, genome organization, and origin of human adenovirus type 11. Virology 309:152-165.
34. Sullivan, N. J., T. W. Geisbert, J. B. Geisbert, L. Xu, Z. Y. Yang, M. Roederer, R. A. Koup, P. B. Jahrling, and G. J. Nabel. 2003. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424:681-684.
35. Sullivan, N. J., A. Sanchez, P. E. Rollin, Z. Y. Yang, and G. J. Nabel. 2000. Development of a preventive vaccine for Ebola virus infection in primates. Nature 408:605-609.
36. + T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J. Virol. 78:2666-2673.
37. + T cells: implications for an efficient vaccination strategy. Gene Ther. 10:243-250.
38. van der Laan, W. H., P. H. Quax, C. A. Seemayer, L. G. Huisman, E. J. Pieterman, J. M. Grimbergen, J. H. Verheijen, F. C. Breedveld, R. E. Gay, S. Gay, T. W. Huizinga, and T. Pap. 2003. Cartilage degradation and invasion by rheumatoid synovial fibroblasts is inhibited by gene transfer of TIMP-1 and TIMP-3. Gene Ther. 10:234-242.
39. Vogels, R., D. Zuijdgeest, R. van Rijnsoever, E. Hartkoorn, I. Damen, M. P. de Bethune, S. Kostense, G. Penders, N. Helmus, W. Koudstaal, M. Cecchini, A. Wetterwald, M. Sprangers, A. Lemckert, O. Ophorst, B. Koel, M. van Meerendonk, P. Quax, L. Panitti, J. Grimbergen, A. Bout, J. Goudsmit, and M. Havenga. 2003. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J. Virol. 77:8263-8271.
40. Wijnberg, M. J., P. H. Quax, N. M. Nieuwenbroek, and J. H. Verheijen. 1997. The migration of human smooth muscle cells in vitro is mediated by plasminogen activation and can be inhibited by alpha2-macroglobulin receptor associated protein. Thromb. Haemost. 78:880-886.
41. Xiang, Z., G. Gao, A. Reyes-Sandoval, C. J. Cohen, Y. Li, J. M. Bergelson, J. M. Wilson, and H. C. Ertl. 2002. Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J. Virol. 76:2667-2675.
42. Yang, Z. Y., L. S. Wyatt, W. P. Kong, Z. Moodie, B. Moss, and G. J. Nabel. 2003. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J. Virol. 77:799-803.
43. Zakhartchouk, A., Y. Zhou, and S. K. Tikoo. 2003. A recombinant E1-deleted porcine adenovirus-3 as an expression vector. Virology 313:377-386.